NASD · Healthcare · Drug Manufacturers - Specialty & Generic · USA
Liquidia Corp is a mid cap company (market value between $2 billion and $10 billion) in the Drug Manufacturers - Specialty & Generic industry.
Liquidia Corp commercializes treatments for rare lung and heart diseases. The company generates revenue from YUTREPIA, an inhaled treprostinil powder for these conditions, and from profit-sharing on a generic treprostinil injection marketed by Sandoz. It operates a commercial field force in the United States targeting healthcare providers involved in treating these patient populations.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Liquidia Corp stock.
Slightly overvalued: intrinsic value $53.50 per share, market price $56.73, margin of safety -6.0% (as of 2026-11-17).
Discounting its cash flows at 7.7% (average of 2 methods) values the shares at $53.50; the price of $56.73 is 6% above that value, and 82% of that value comes from beyond year five.
17 more funds hold it; the full list is part of the paid plan.
All 82 Drug Manufacturers - Specialty & Generic stocks
9 more in this industry show a wider margin of safety.
LQDA is slightly overvalued (as of the 2026-11-17 close). Discounting its cash flows at 7.7% (average of 2 methods) values the shares at $53.50; the price of $56.73 is 6% above that value, and 82% of that value comes from beyond year five.
$53.50 per share (as of the 2026-11-17 close), against a market price of $56.73. That is a margin of safety of -6.0%. The value is the average of the 2 valuation methods that apply to this company, recomputed every night after the US close.